MedTrace Logo

Lorazepam for the Analgosedation of Pediatric Patients in Mechanical Ventilation.

NCT04646135 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-11-27

No results posted yet for this study

Summary

The aim of this study is to better define the pharmacokinetic and pharmacodynamic profile of lorazepam for the analgosedation in pediatric intensive care unit. This will help to better define the dosages and administration modalities (bolus or continue infusion) required to achieve analgosedation with lorazepam in pediatric patients undergoing mechanical ventilation.

Conditions

  • Analgesia

Interventions

DRUG

Lorazepam 4 mg/ml

Lorazepam will be administered intravenously according to the scheduled sequences.

Sponsors & Collaborators

  • Ministero della Salute, Italy

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • Bambino Gesù Hospital and Research Institute

    lead OTHER

Principal Investigators

  • Marco Marano, MD · Bambino Gesù Hospital and Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-07-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646135 on ClinicalTrials.gov